{"entity":{"id":"nct06742892","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","aka":[],"tldr":"A phase 2 trial of HLX43 DOSE 1 in hepatocellular carcinoma, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy is a phase 2 interventional study registered as NCT06742892 by Shanghai Henlius Biotech, with 90 participants planned, started 2025-03-03 and due to reach its primary completion in 2026-10-31. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06742892","url":"https://clinicaltrials.gov/study/NCT06742892"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06742892","phase":"2","setting":"A Phase II Clinical Study to Evaluate HLX43 (Anti-PD-L1 ADC) in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy","sponsor":"Shanghai Henlius Biotech","enrolled":90,"outcomes":[]},"route":"/trials/nct06742892/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}